News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

William Wierda, MD, PhD, MD Anderson Cancer Center

Articles by William Wierda, MD, PhD, MD Anderson Cancer Center

Future Directions in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

PI3 Kinase Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapeutic Sequencing in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

MURANO Trial Update in R/R CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Utility of MRD Testing in CLL Management

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Venetoclax and Obinutuzumab in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Second-Generation BTK Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapies in the Pipeline for Frontline CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Telemedicine for Patients With CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Treating CLL During COVID-19

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Frontline Treatment Options in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

COVID-19 and CLL Treatment Initiation

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Selecting First-Line Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Advances in Frontline Therapy for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Impact of COVID-19 on Management of CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Initial Work-up for Chronic Lymphocytic Leukemia

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Latest Updated Articles

PI3 Kinase Inhibitors in CLL
Published: July 30th 2020 | Updated:
BTK Inhibitors in CLL: Ibrutinib
Published: July 30th 2020 | Updated:
Frontline Treatment Options in CLL
Published: July 30th 2020 | Updated:
Therapies in the Pipeline for Frontline CLL
Published: July 30th 2020 | Updated:
Second-Generation BTK Inhibitors in CLL
Published: July 30th 2020 | Updated:
Treating CLL During COVID-19
Published: July 30th 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma